Clinical Trial Update: A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial results for enfortumab vedotin in Chinese participants with locally advanced or metastatic urothelial cancer who previously received platinum chem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Cancer

Drugs mentioned

• Enfortumab Vedotin (enfortumab vedotin)

Snippet

Sponsor: Astellas Pharma China, Inc. | Conditions: Metastatic Urothelial Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-09-13